{"entity":{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","aka":["FLORA-5"],"tldr":"A phase 3 trial testing Oregovomab in ovarian cancer, active and no longer recruiting.","summary":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is a phase 3 interventional study registered as NCT04498117, led by CanariaBio with Gynecologic Oncology and IQVIA Pty, and active but no longer recruiting on the registry. Official title: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. Planned enrolment is 615 participants (actual). The study started in 2020-08-25 and primary completion is expected in 2026-12-26. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT04498117","url":"https://clinicaltrials.gov/study/NCT04498117"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["oregovomab"],"companies":["canariabio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04498117","phase":"3","setting":"A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma","sponsor":"CanariaBio","participation":[{"nct":"NCT04498117","source":"https://clinicaltrials.gov/study/NCT04498117","fetchedAt":"2026-10-07T16:53:21.208Z","studySha256":"8991dbeab7883f7ea471812611739d373a1ec8b7e781531d7186a05724ca122a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-01","leadSponsor":"CanariaBio Inc.","collaboratorCount":2,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":615,"enrolmentType":"ACTUAL","siteCount":148,"recruitingSiteCount":0,"countries":["Argentina","Belgium","Brazil","Canada","Chile","Czechia","Hungary","India","Italy","Mexico","South Korea","Spain","Taiwan","United States"]}],"started":"2020-08-25","startedType":"actual","enrolled":615,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04498117/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/"}],"company":[{"id":"canariabio","kind":"company","name":"CanariaBio","route":"/companies/canariabio/"}]}}